HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Sales increase 6.7% to $138.4 mil. for fiscal first quarter (ended April 30), Gucci reports June 21. Yves Saint Laurent cosmetics sales increased 15.9% to $40 mil., while fragrance revenues were off 1% at $60.9 mil. Gucci purchased Sanofi's beauty business, which included YSL and couture, from Artemis, a holding company for Pinault-Printemps-Redoute, in November (1"The Rose Sheet" Nov. 22, 1999, p. 4). LVMH and PPR have engaged in talks to resolve disagreements surrounding PPR's alliance with Gucci. The two companies had been negotiating a sale of LVMH's 20 mil. Gucci shares for $100 per share, but the deal fell through

You may also be interested in...

Gucci Acquires $583.4 Mil. Sanofi Beauty Business From Artemis

Gucci is purchasing Sanofi Beaute from Artemis for $1 bil., giving the fashion house Yves Saint Laurent fragrances and cosmetics, Roger & Gallet, and fragrance licenses for Van Cleef & Arpels, Oscar de la Renta, Fendi and Krizia. Sanofi beauty sales total $583.4 mil.

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts